Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pneumonia vaccine shows promise in large adult trial

NCT ID NCT06182124

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested new pneumococcal vaccines in over 1,300 adults aged 18 and older to see if they are safe and help the body fight off pneumococcal disease. Participants received one shot of either a new vaccine or an existing one, and were monitored for side effects and immune response for up to 12 months. The goal is to find a vaccine that offers better protection against pneumonia and related infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

1,363 people

The number who actually took part.

Started

Dec 2023

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants ≥18 to\<50 years of age (Stage 1) and ≥50 years of age (Stage 2, Stage 3, and Stage 4) at the time of consent * Adults determined by clinical assessment to be eligible for the study, including adults with preexisting stable disease within 12 weeks before receipt of study intervention * Participants willing to use acceptable contraception for at least 28 days after study intervention; female participants not of childbearing potential; male participants unable to father children * Phase 1 (Stage 1): Adults 18 through 49 years of age with no history of ever receiving a pneumococcal vaccine (ie, pneumococcal vaccine-naïve) * Phase 2 (Stages 2, 3, and 4): Adults ≥50 through 64 years of age with no history of ever receiving a pneumococcal vaccine (ie, pneumococcal vaccine-naïve) and adults 65 years of age and older with either no history of ever receiving a pneumococcal vaccine or who received PPSV23 \>5 years prior to the first vaccination in this study (ie, experienced) Exclusion Criteria: * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component in pneumococcal conjugate vaccines and any other diphtheria toxoid-containing vaccine * Serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study * Medical or psychiatric condition (recent or active suicidal ideation/behavior or laboratory abnormality) that may increase risk of study participation or make participant inappropriate for the study * Known or suspected immunodeficiency or other conditions associated with immunosuppression * Planned receipt of any licensed or investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation * Receipt of any inactivated or otherwise nonlive vaccine within 14 days or any live vaccine within 28 days before administration of study intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumococcal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumococcal disease

Contacts and locations

Locations

  • AMR Clinical

    Knoxville, Tennessee, 37909, United States

  • AMR Clinical

    Knoxville, Tennessee, 37920, United States

  • Accellacare - Wilmington

    Wilmington, North Carolina, 28401, United States

  • Alliance for Multispecialty Research, LLC

    Doral, Florida, 33172, United States

  • Alliance for Multispecialty Research, LLC

    New Orleans, Louisiana, 70119, United States

  • Clinical Research Atlanta

    Stockbridge, Georgia, 30281, United States

  • Clinical Trials of Texas, LLC dba Flourish Research

    San Antonio, Texas, 78229, United States

  • DM Clinical Research

    Tomball, Texas, 77375, United States

  • DM Clinical Research- Cyfair

    Houston, Texas, 77065, United States

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research

    Sugar Land, Texas, 77478, United States

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research

    Tomball, Texas, 77375, United States

  • Headlands Horizons LLC

    Brownsville, Texas, 78526, United States

  • Headlands Research - Detroit

    Southfield, Michigan, 48034, United States

  • IMA Clinical Research San Antonio

    San Antonio, Texas, 78229, United States

  • IMA Evaluations, LLC dba IMA Clinical Research

    Tarrytown, New York, 10591, United States

  • Indago Research & Health Center, Inc

    Hialeah, Florida, 33012, United States

  • J. Lewis Research, Inc.

    Salt Lake City, Utah, 84109, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah, 84109, United States

  • Optimal Research

    Peoria, Illinois, 61614, United States

  • Rochester Clinical Research, LLC

    Rochester, New York, 14609, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.